Saturday 17 October 2026
Export VRAX’s income statement to Excel — free account
Virax Biolabs Group Limited
VRAX Healthcare Biotechnology
Virax Biolabs Group Limited’s revenue for fiscal 2026 (year ended March 2026) was $12,400.00, up 96.8% from fiscal 2025.
1.45
0.17
−10.49%
Follow VRAX
| Older periods | Sep '24 | Mar '25 | Sep '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+7 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
10.54 | 6.33 | 9.63 | 9.44 | |
Current Ratio |
11.57 | 7.27 | 11.35 | 9.97 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
2.36% | 0.51% | 3.42% | 0.34% | |
Debt/Equity |
0.03 | 0.01 | 0.04 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(1.57) | (1.76) | (0.65) | (0.58) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(2.17) | (5.17) | (2.90) | (4.88) | |
Working Capital |
7.34 | 4.22 | 3.78 | 6.14 | |
Capital Expenditures |
(0.25) | (0.60) | (0.14) | (0.26) | |
Net Current Asset Value |
7.01 | 3.93 | 3.51 | 5.84 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.02 | 0.18 | 0.12 | |
Average Payables |
0.57 | 0.66 | 0.42 | 0.35 | |
Average Inventory |
0.07 | 0.06 | 0.04 | — | |
Average Assets |
7.37 | 8.12 | 6.37 | 6.90 | |
Average Common Equity |
6.29 | 7.18 | 5.59 | 6.24 |
Columns are period end dates